ESMO 2023

Highlights in eBC

DATO-DX - where is it going?

Preoperative checkpointinihition in ER+ disease

5 year follow-up

Remarkable efficacies in patients with HER2+ mBC with brain metastases

My highlights of ESMO23 in metastatic breast cancer

New 3rd line therapy for RCC

Early use of enzalutamide in advanced prostate cancer

The FGFR story in bladder cancer at ESMO23

Lu-PSMA leads forward

Clearing up non-clear cell RCC

When the history of ADC is written: Redefining first-line standard of care in mUC!

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

ALINA - immediate change of practice!

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

My highlights from ESMO 2023

Tarlatamab in SCLC

Anticipated updates and exciting new data for checkpointinhibitors

What is your definition of triple-negative breast cancer?

New and better biomarkers are needed!

Data updates for CDK4/6 inhibitors in EBC at ESMO23 - implications for clinical practice

What was the most exciting news at ESMO23?

My highlights of ESMO23 in early breast cancer

Detailed view of nodal-negative patients

Negative EFS results from NeoTrip

Consolidation of data in early HR+ and triple-negative breast cancer

Pembrolizumab solidifies as SOC in early-stage TNBC

5 year follow-up

Neoadjuvant IO - is their new strategy in HR+ breast cancer

Immunoncology in eBC - triple negative and more?

MonarchE - trial update

Analysis of tumour microenvironment and immunophenotype in TNBC

Metabolomics reveal differential expression of OMEGA 3 & OMEGA 6 in neoadjuvant treatment

Prognostic score in early HR+/HER2-BC: translational data from ADAPT

Our guidelines are correct

Highlights in eBC

Preoperative checkpointinihition in ER+ disease

Clinically relevant effect of pembro also in PCR

Ribociclib effective in all subtypes

Use of immunotherapy in the perioperative setting of luminal Her2- BC

ER-low corresponds diagnostically to ER-0 breast cancer

HR+ study with > 20 % PCR

Carry-over effects in monarchE confirmed

New data on neoadjuvant immunotherapy

Nouvelles données sur l'immunothérapie néoadjuvante

Punti salienti in eBC

Studio NeoTrip: negativi i risultati

MonarchE - mise à jour de l'essai

La Metabolomica svela l’importanza di OMEGA 3 & OMEGA 6 nel condizionare la risposta alla terapia neo-adiuvante

New targets, new linker, new ADCs - much more to learn with new therapies!

How to organize a molecular tumorboards in breast cancer?

What was the most exciting news at ESMO23?

New ADC for metastatic breast cancer?

ADCs in HER2+, HER2low and TNBC - what is the future of ADCs?

Improvement of therapy outcome by app-based patient education

OP seems to be dispensable for super responders

Still on track for success in HER2-low MBC

TULIP: Trastuzumab duocarmazine without OS benefit

My highlights of ESMO23 in metastatic breast cancer

Can surgery be spared following primary systemic therapy?

Benefit for SG even after intensive pretreatment

New ADC in HR+ disease

Fulvestran better than anastrozole, but no survival benefit

Even more new generation ADCs in breast cancer?

TROP2 expression as a potential mechanism of resistance in HER2+ patients

T-DXd in HER2+ patients with brain metastases

Our guidelines are correct

DATO-DX - where is it going?

Highlights in mBC

Improved oncological therapy with the smartphone

Remarkable efficacies in patients with HER2+ mBC with brain metastases

Abemaciclib remains consistent in 5-year follow-up

Patient-centered molecular medicine - a new approach

Robust data from the monarchE

T-DXd - new standard of care for brain mets?

T-DXd also effective for brain metastases

OP-1250 (Palezestrant) confirms the role of SIRDs after CDK4/6i

Duvalumab + Dato-DXd effective

HER2DX in the PHERgain trial

Dato-DXd - new player in advanced luminal disease

HS20089 - a novel ADC is coming for TNBC

ADC + Immunotherapy - the BEGONIA study paradigm

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par le cancer triple negative

HS20089 - un nuovo ADC che si affaccia sulla scenda del TNBC

HER2DX en el estudio PHERgain

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym leczeniu systemowym?

La expresión de TROP2 como potencial mecanismo de resistencia en pacientes HER2+.

Punti salienti in mBC

Dato-DXd - nowy gracz w zaawansowanym raku luminalnym

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei SERDs dopo le cicline

T-DXd - nowy standard postępowania w przerzutach do mózgu?

Lo studio BEGONIA nelle paziento con tumore triplo negativo

Should we use zoledronic acid in all ADT patients?

Targeted therapy will move forward - but more robust data is needed.

The optimal timing of RT after radical prostatectomy and QoL data of ENZA therapy in nmHSPC

What is the future of immune therapy in prostate cancer?

IO therapy in metastatic prostate cancer.

CXCR2 inhibitor in PCa

EMBARK expands ENZA indication to PCa

Embark without fear

STAMPEDE. Bone prediction not for everyone - better risk stratification for PCa

Brave New World in mCRPC

Early use of enzalutamide in advanced prostate cancer

Lu-PSMA leads forward

ENZA P:Trial and controversies

EMBARK - Quality of Life

Big data and AI prediction tools

Salvage radiotherapy the new standard

RADICALS RT: Trial and controversies

Precision medicine at mCRCP

Longterm toxicity of adjuvant RT after prostatectomy

Immunotherapy in metastatic PCa

Negative data for pembrolizumab in mHSCPC & mCRPC

PSMAfore unleashes urooncologic opportunity

Osteoprotection at mHSPC

Combination of radioligand therapy with chemotherapy useful

TITAN: ultra-low PSA = best prognosis

PSMA FORE: Trial and controversies

When immunotherapy is probably not the best choice: The case of untreated metastatic prostate cancer

STAMPEDE data. Skelettstärkande och riskstratifiering.

CXCR2 hämmare och prostatacancer

Immunterapi vid prostatacancer

Big Data och AI för prediktion vid prostatacancer

Cuando la inmunoterapia probablemente no es la mejor elección: El caso del cancer de próstata avanzado en pacientes no seleccionados

EMBARK och livskvalitet

Part1: New standard of care in first line urothelial cancer?!

Part 2: New standard of care in first line urothelial cancer!

FGFR inhibitors and ADC combinations in urothelial cancer - new options for the future?!

The FGFR story in bladder cancer at ESMO23

DAD, DAD-IO

Unique bladder delivery system of gemcitabine herolds remarkable response

EV + Pembro as standard of care in first-line therapy of bladder cancer

Chemo-IO establishes itself in the first-line treatment of bladder cancer

FGFR inhibitors: What is the best scenario for this family of compounds?

When the history of ADC is written: Redefining first-line standard of care in mUC!

New SoC in firstline bladder cancer

Amazing new data in bladder cancer

Στιγμιότυπα για τον καρκίνο των νεφρών και της ουροδόχου κύστης στο ESMO23

L'histoire du FGFR dans le cancer de la vessie à l'ESMO23

Reescribiendo la historia de una enfermedad: Nuevo estándar de tratamiento en primera linea en cancer urotelial avanzado

Inhibidores de FGFR: Cual es el mejor escenario para esta familia de fármacos?

Important new treatment option but only for subset of patients?

Where does the future therapy go in renal cell carcinoma?

Is de-escalating therapy ready for prime-time?

Clearing up non-clear cell RCC

New mode of action in mRCC - ready for prime time?

Belzutifan - whats next kidney cancer?

Intermittent therapy also possible with TKIs

Kidney cancer highlights at ESMO23

New 3rd line therapy for RCC

Belzutifan in later lines of therapy

ALINA - remarkably positive DFS in early-stage ALK+ NSCLC

Moving patients to the neoadjuvant setting in non-metastatic NSCLC

Perioperativ immunotherapy for all resectable stage II-IIIb NSCLC patients

Perioperative IO: OS-benefi from KEYNOTE-671

ALINA - a new paradigm in operated NSCLC with ALK-fusion

My highlights from ESMO 2023

Big improvements in early stage and a subset of metatstic NSCLC

Neoadjuvant chemo-immunotherapy new standards in early & advanced NSCLC

Adjuvant alectinib in patients with early-stage ALK+ NSCLC

Substantial improvement in local regional NSCLC

Circulating DNA in AEGEAN trial

ALINA - immediate change of practice!

Scene is set for inductive immunotherapy

Perioperatieve chemo-immunotherapie voor alle patienten met resectabel stadium II-IIIB NSCLC?

I miei punti salienti di ESMO 2023

Les points forts de l'ESMO 2023

ALINA - un nouveau paradigme dans cBNPC avec la fusion ALK

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

Activating EGFR-mutation - what's coming up?

ESMO2023-impact on everyday practice!

Evolving landscape of ADCs

Rare oncogenic alterations: landmark results on exon 20 insertion & confirming data on RET fusion+ NSCLC

Changing treatment landscape in EGFR-mutated NSCLC

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

NRG fusions: a new drugable target?

Substantial improvement in rare alterations

Does immunotherapy still have a place in EGFR-positive mNSCLC?

MARIPOSA: Trial and controversies

Amivantamab at progression? MARIPOSA-2 trial

By unanimous decision and still the champion – docetaxel!

Brain metastases – options to improve the systemic treatment

Amivantamab as a new SoC for EGFR Exon 20 Insertion-mutated aNSCLC

MARIPOSA II: Trial and controversies

Treatment sequences for EGFR-mutated Patients

Big improvements in early stage and a subset of metatstic NSCLC

Practice changing results on exon 20 insertion mNSCLC

Do ADCs have brain activity?

My highlights from ESMO 2023

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

New standard of care for metastatic EGFR exon 20 insertion mutated NSCLC

PAPILLON - bringing together therapy for the 1st line

LIBRETO - a positive study, but was it necessary?

Amivantamab upfront? MARIPOSA trial

TROPION-Lung01: positive development

Adagrasib + pembrolizumab in patients with KRASG12C mutation

Amivantamab upfront? MARIPOSA trial

L’amivantamab, nouveau standard de traitement pour les EGFR exon 20

Nieuwe standaard voor gemetastaseerd EGFR exon20 insertie gemuteerd NSCLC

Veränderte Behandlungslandschaft bei EGFR-mutiertem NSCLC

Les points forts de l'ESMO 2023

I miei punti salienti di ESMO 2023

Datopotamab deruxtecan - new SOC in 2nd line adv/met NSCLC?

Amivantamab at progression? MARIPOSA-2 trial

Heeft immunotherapie nog een plek in de behandeling van EGFR-positief gemetastaseerd NSCLC?

Gros progrès dans les traitments medicaeux des stades precocers et par des sous-groupes au stade métastatique

Quelles séquences thérapeutiques pour les patients EGFR mutés

Impact of T-cell engagers in SCLC

Tarlatamab in SCLC

New hope for patients with SCLC

A new option in relapsed SCLC

Neue Hoffnung für Patienten mit SCLC

First data on luveltamab in multiline treatment for endometrial cancer

New data on sarkomas

Precision oncology in CUP

Update on gynaecological cancers

Evolution of the revolution - the RUBY trial

PCO Therapeutics

New data on H&N Cancer